Recently, in clinical trial, NGM282, an engineered FGF19 analog, could significantly reduce liver fat content in patients with NASH and remarkably improve ALP and transaminase levels in patients with PBC (Harrison et al., 2018; Mayo et al., 2018). This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatohepatitis.